How Biomarin Beat Expectations in Q2

You won't find many people who would complain about BioMarin Pharmaceutical's (NASDAQ: BMRN) performance so far this year. The stock has soared 68% since its March low and is now up more than 40% year to date.

BioMarin announced its second-quarter results after the market closed on Tuesday. And it didn't disappoint. Here are the highlights from BioMarin's Q2 update.

Image source: Getty Images.

Source Fool.com